Merck Company Stock Today
| MRK Stock | USD 103.12 1.50 1.48% |
Performance0 of 100
| Odds Of DistressLess than 6
|
Merck is selling for 103.12 as of the 28th of November 2024. This is a 1.48 percent increase since the beginning of the trading day. The stock's last reported lowest price was 101.64. Merck has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Note, on November 14, 2024, Representative Michael McCaul of US Congress acquired $50k to $100k worth of Merck Company's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of January 1978 | Category Healthcare | Classification Health Care |
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 2.53 B outstanding shares of which 26.32 M shares are now shorted by investors with about 2.6 days to cover. More on Merck Company
Moving together with Merck Stock
| 0.78 | VALN | Valneva SE ADR | PairCorr |
| 0.83 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.87 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.86 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Merck Stock
Follow Valuation Options Odds of Bankruptcy
Fiscal Year End 6th of February 2025
Merck Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Kenneth Frazier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | Showing 3 out of 4 themes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Merck & Company Inc, Marka S.A., Merck & Company Inc, Merck & Company Inc] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Dow Jones Industrial, DAX Index, NYSE Composite, NYSE 100 Index, ARCA Major Markets, SP 500 Index, ARCA Institutional, ARCA Pharmaceutical, BTRINVSTNG 100 INDEX, DAX Price, BETTERINVESTING 100 INDEX, HDAX Performance, HDAX Price, SP 100, Robots And Drones, Macroaxis Picks, Giant Impact, Compulsion, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMerck can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Merck's financial leverage. It provides some insight into what part of Merck's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merck Company (MRK) is traded on New York Stock Exchange in USA. It is located in 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 and employs 70,000 people. Merck is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 257.06 B. Merck Company runs under Pharmaceuticals sector within Health Care industry. The entity has 2.53 B outstanding shares of which 26.32 M shares are now shorted by investors with about 2.6 days to cover.
Merck Company has about 12.69 B in cash with 13.01 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.44.
Check Merck Probability Of Bankruptcy
Ownership AllocationMerck Company maintains a total of 2.53 Billion outstanding shares. The majority of Merck outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Merck Company to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Merck Company. Please pay attention to any change in the institutional holdings of Merck as this could imply that something significant has changed or is about to change at the company. Please note that on November 14, 2024, Representative Michael McCaul of US Congress acquired $50k to $100k worth of Merck Company's common stock.
Check Merck Ownership Details
Merck Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 24.7 M | |
| Legal & General Group Plc | 2024-06-30 | 23.4 M | |
| Deutsche Bank Ag | 2024-06-30 | 20.8 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 19.2 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 18.8 M | |
| Ubs Asset Mgmt Americas Inc | 2024-09-30 | 17.8 M | |
| Ameriprise Financial Inc | 2024-06-30 | 16.6 M | |
| Franklin Resources Inc | 2024-09-30 | 16.1 M | |
| Amvescap Plc. | 2024-06-30 | 15.8 M | |
| Vanguard Group Inc | 2024-09-30 | 249.8 M | |
| Blackrock Inc | 2024-06-30 | 207.3 M |
Merck Historical Income Statement
Merck Stock Against Markets
Merck Corporate Directors
| Thomas Glocer | Lead Independent Director | Profile | |
| Christine Seidman | Independent Director | Profile | |
| Kathy Warden | Independent Director | Profile | |
| Paul Rothman | Independent Director | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Dividend Share 3.04 | Earnings Share 4.78 | Revenue Per Share 24.931 | Quarterly Revenue Growth 0.044 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.